Brian Clarke, MD FRCPC FACC
Associate Professor, Division of Cardiology
Foothills Medical Centre, Libin Cardiovascular Institute, University of Calgary
Department of Cardiac Sciences, University of Calgary, Libin Cardiovascular Institute
Cardio-oncology is a rapidly growing field aimed at minimizing the effects of cardiovascular morbidity and mortality in cancer survivors. To meet this aim, patients are assessed at baseline to define their risk of cardiotoxicity and then followed closely during and after chemotherapy to assess for early signs or symptoms of cardiovascular disease. Cardiac imaging plays an essential role in the baseline assessment and serial follow-up of cardio-oncology patients. The objectives of this workshop calls upon the expertise of 5 individuals and audience interaction to highlight the struggles of cancer survivors patients and provide understanding into the mechanisms of cardiotoxicity of several common chemotherapeutic agents associated with an increased risk for left ventricular systolic dysfunction and to outline recommendations regarding the baseline assessment and serial follow-up of cardio-oncology patients.
Dr. Thavendiranathan is cardiologist at the Peter Munk Cardiac Centre and is the director of the Ted Rogers Centre’s cardiotoxicity prevention program. Among oncologists, Dr. Thavendiranathan believes that opinions vary about how significant an issue cardiotoxicity is. Their attention is applied exactly where it needs to be, yet what often is lost in exchanges between oncologists and their patients is an honest assessment of the potential long-term side effects of chemotherapy.
Dr White leads the Cardiotoxicity Prevention Research Initiative (CAPRI), which is a partnered provincial initiative between the University of Calgary, University of Alberta. With several planned phases, CAPRI’s goals are to help standardize care pathways for breast cancer patients at elevated risk of heart damage and to allow for improved data capture and monitoring across Alberta. This is a critical first step in the team’s ultimate goal of predicting, detecting and treating damage to the cardiovascular system related to cancer therapies—which can cause permanent decreases in heart function and sometimes death.
Dr Brian Clarke, MD, Associate Professor, Cardiology, is a heart failure cardiologist at Libin Cardiovascular Institute, Alberta Health Services & the University of Calgary, co-director of the cardio-oncology program with experience in setting up and running a cardio-oncology program.
Dr. Swiggum is the Medical Director of the Heart Function Clinic and Cardiac Rehabilitation program at the Royal Jubilee Hospital, Victoria, B.C. since 2005, where she is a Clinical Associate Professor at the University of British Columbia.
Dr. Tournoux is cardiologist at the CHUM and assistant clinical professor at the Université de Montréal. He is the president of the Quebec Heart Failure Society with special interest in cardio-oncology.